1. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008;8:117. [DOI:10.1186/1471-2458-8-117]

2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47. [DOI:10.1001/jama.298.17.2038]

3. Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2010;55:S23-33. [DOI:10.1053/j.ajkd.2009.09.035]

4. Lankhorst CE, Wish JB. Anemia in renal disease: diagnosis and management. Blood Rev 2010;24:39-47. [DOI:10.1016/j.blre.2009.09.001]

5. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 2005;68:228-36. [DOI:10.1111/j.1523-1755.2005.00397.x]

6. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85-97. [DOI:10.1161/CIRCULATIONAHA.106.678342]

7. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006;1:8-18. [DOI:10.2215/CJN.00730805]

8. Dickstein K, Cohen-Solal A, Filippatos G, McMurray J, Ponikowski P, Poole-Wilson P, et al. ESC Committee for Practice Guidelines (CPG) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89. [DOI:10.1016/j.ejheart.2008.08.005]

9. Naik RP, Derebail VK, Grams ME, Franceschini N, Auer PL, Peloso GM, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA 2014;312:2115-25. [DOI:10.1001/jama.2014.15063]

10. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713-35. [DOI:10.1053/j.ajkd.2014.01.416]

11. Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL, eds. Brenner and Rector's The Kidney. 10th ed. New York: Elsevier; 2015.

12. Xie C, Zeng M, Shi Z, Li S, Jiang K, Zhao Y. Association between selenium status and chronic kidney disease in middle-aged and older Chinese based on CHNS data. Nutrients 2022;14:2695. [DOI:10.3390/nu14132695]

13. Lin T, Chen J, Liaw J, Juang J. Trace elements and lipid peroxidation in uremic patients on hemodialysis. Biol Trace Elem Res 1996;51:277-83. [DOI:10.1007/BF02784082]

14. System USRD. 2018 USRDS annual data report: epidemiology of kidney disease in the United States. Available from: https://www usrds org/adr aspx. 2018.

15. Ho E, Galougahi KK, Liu C-C, Bhindi R, Figtree GA. Biological markers of oxidative stress: applications to cardiovascular research and practice. Redox Biol 2013;1:483-91. [DOI:10.1016/j.redox.2013.07.006]

16. Miura Y, Nakai K, Suwabe A, Sera K. Trace elements in renal disease and hemodialysis. Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 2002;189:443-9. [DOI:10.1016/S0168-583X(01)01122-3]

17. Zima T, Tesař V, Mestek O, Němeček K. Trace elements in end-stage renal disease. Blood Purif 1999;17:187-98. [DOI:10.1159/000014395]

18. Duntas LH, Benvenga S. Selenium: an element for life. Endocrine 2015;48:756-75. [DOI:10.1007/s12020-014-0477-6]

19. Smith JK, Johnson AB, Williams CD, et al. Selenium and thyroid function in end-stage renal disease: A comprehensive cross-sectional study. Nephrol Dial Transplant 2022;37:1502-10.

20. Gorini F, Sabatino L, Pingitore A, Vassalle C. Selenium: an element of life essential for thyroid function. Molecules 2021;26:7084. [DOI:10.3390/molecules26237084]

21. Zima T, Tesař V, Mestek O, Němeček K. Trace Elements in End-Stage Renal Disease: 2. Clinical Implication of Trace Elements. Blood Purif 1999;17:187-98. [DOI:10.1159/000014395]

22. Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256-68. [DOI:10.1016/S0140-6736(11)61452-9]

23. Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol 2017;2017:1297658. [DOI:10.1155/2017/1297658]

24. Feingold KR. The effect of endocrine disorders on lipids and lipoproteins. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2023.

25. Schomburg L. Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat Rev Endocrinol 2012;8:160-71. [DOI:10.1038/nrendo.2011.174]

26. Iglesias P, Díez J. Thyroid dysfunction and kidney disease. Eur J Endocrinol 2009;160:503-15. [DOI:10.1530/EJE-08-0837]

27. Shi Y, Zou Y, Shen Z, Xiong Y, Zhang W, Liu C, et al. Trace elements, PPARs, and metabolic syndrome. Int J Mol Sci 2020;21:2612. [DOI:10.3390/ijms21072612]

28. Köhrle J. The deiodinase family: selenoenzymes regulating thyroid hormone availability and action. Cell Mol Life Sci 2000;57:1853-63. [DOI:10.1007/PL00000667]

29. Zimmermann MB, Köhrle J. The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health. Thyroid. 2002;12(10):867-78. [DOI:10.1089/105072502761016494]

30. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808. [DOI:10.1046/j.1523-1755.2003.00803.x]

31. Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev 1996;17:45-63. [DOI:10.1210/edrv-17-1-45]

32. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease--what have we learned in 10 years? Semin Dial 2010;23:498-509. [DOI:10.1111/j.1525-139X.2010.00784.x]

33. Beckett GJ, Arthur JR. Selenium and endocrine systems. J Endocrinol 2005;184:455-65. [DOI:10.1677/joe.1.05971]

34. Krachler M, Wirnsberger G, Irgolic KJ. Trace element status of hemodialyzed patients. Biol Trace Elem Res 1997;58:209-21. [DOI:10.1007/BF02917472]

35. Heymsfield SB, Bethel RA, Hall EC, Mills JB, Moseley MH, Kostyo JL, et al. Anabolic actions of reduced and S-carbamidomethylated human growth hormone and its plasmin digest in man. J Clin Invest 1977;60:563-70. [DOI:10.1172/JCI108808]

36. Roman M, Jitaru P, Barbante C. Selenium biochemistry and its role for human health. Metallomics 2014;6:25-54. [DOI:10.1039/C3MT00185G]

37. Burk RF, Hill KE. Regulation of selenium metabolism and transport. Ann Rev Nutr 2015;35:109-34. [DOI:10.1146/annurev-nutr-071714-034250]